Please assess the completion status of the following clinical trial:

Trial Title: Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced kidney cancer~Exclusion Criteria:~* Previous treatment for kidney cancer, except surgical removal of kidney tumor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SUNITINIB MALATE. (Type: EXPERIMENTAL): Sunitinib malate starting dose 37.5 mg daily continuous daily schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).